A new vaccine against respiratory syncytial virus (RSV), Abrysvo, from Pfizer, is now available for prescription in Spain. RSV is the leading cause of bronchiolitis and causes between 7,000 and 14,000 hospitalizations of infants in Spain annually.
This vaccine is indicated for the protection of infants under six months of age through the immunization of their mothers, and of the adult population from 60 years old. At the moment the vaccine is only financed in the case of pregnant women.